
India has the potential to increase global clinical trials in the country by five times, according to a joint report by the USA India Chamber of Commerce and PwC India. India has an overall clinical trial participation of just 3% but contributes 15% of the global burden of most high-prevalent diseases, representing the untapped potential for top pharma. Experts highlight the significant opportunities for biopharma companies to leverage India's rich diversity and robust healthcare infrastructure to develop innovative treatments. They encourage them to focus on the key enablers of innovation and strategic partnerships in India.
Like
Save
Share